在喘发作管理中对全身皮质类固醇的反应的表型化 (PRISMA)
Carlos Celis-Preciado1,2, Simon Leclerc1,3, Martine Duval1
1Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada.
The European respiratory journal
|February 13, 2025
概括
口服皮质类固醇 (OCS) 改善急性喘肺功能,主要是在患有高2型 (T2) 炎症的患者中,通过血液中异氨基细胞计数 (BEC) 和部分呼出的氧化 (Feno) 表示. 低T2炎症对OCS的反应很小.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 生物标志物研究 生物标志物研究
背景情况:
- 急性喘恶化表现为异质的临床表现.
- 2型 (T2) 炎症生物标志物的作用,特别是血液中乙氨基基酸计数 (BEC) 和部分呼出的氧化 (Feno),在预测急性喘期间口服皮质类固醇 (OCS) 反应方面尚不清楚.
研究的目的:
- 研究T2炎症生物标志物 (BEC和Feno) 与急性喘发作患者对OCS治疗的临床反应之间的关联.
主要方法:
- 一项纵向观察性研究涉及53名患有急性喘的参与者.
- 患者在7天OCS课程之前和之后进行了评估.
- 肺功能 (FEV1) 和喘控制问卷-5分数是主要和次要结局,按BEC和Feno水平的组合分类 (T2-低/低,T2-中,T2-高/高).
主要成果:
- 经过OCS后的支气管扩展后FEV1显著改善,随着更高的BEC-Feno水平而增加 (相互作用的p=0.007).
- T2-高/高组显示出FEV1的最大改善 (0.390±0.512 L),而T2-低/低组显示出最小的变化 (0.017±0.153 L).
- 顺序BEC-Feno分层,而不是症状或初始FEV1,预测FEV1的改善. 喘控制问卷-5分数在所有组都得到改善,在T2-高/高表型中数量达到顶峰.
结论:
- 在急性喘中使用OCS的客观临床改善主要观察到患有高T2炎症 (T2-高事件) 的患者.
- 与慢性喘类似,在急性恶化中较高的T2炎症负担意味着独特的临床和治疗轨迹.
- 与OCS相关的不良事件在所有T2炎症组中均分布.
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
228
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
228
01:26COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:20Asthma: Pathogenesis and Management
374
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
374
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
251
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
251
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K